Merck acquired Bio-Techne for a premium of $11.3 billion, causing Techne's stock to jump 20% in pre-market trading.

According to the 36Kr APP, American life science company Bio-Techne (TECH.US) surged more than 20% during pre-market trading on Thursday. This came after German Merck KGaA announced its agreement to acquire the company for $73 per share in cash, with a total enterprise value of around $11.3 billion (approximately 9.9 billion euros).